Teva Pharmaceutical Industries Ltd (TEVJF) EBITDA Margin (2009 - 2026)

Teva Pharmaceutical Industries' (TEVJF) quarterly EBITDA Margin came in at 5.58% in Q2 2026, down 1647.0% YoY from 0.36% in Q2 2025, and down 134.06% on a QoQ basis from 16.37% in Q1 2026.

Teva Pharmaceutical Industries Ltd (TEVJF) EBITDA Margin (2009 - 2026) Analysis & Trends

Teva Pharmaceutical Industries (TEVJF) has 18 years of EBITDA Margin data on file, last reported at 5.58% in Q2 2026.

  • Quarterly EBITDA Margin fell 1647.0% year-over-year to 5.58% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 9.26% (up 341.0% YoY) and the FY2025 annual result came in at 12.5%, up 1433.0% from the prior year.
  • EBITDA Margin retreated to 5.58% in Q2 2026, from 16.37% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 19.69% in Q3 2025 to a low of 25.54% in Q2 2022.
  • A 5-year average of 0.24% and a median of 0.24% in 2023 frame the typical range for EBITDA Margin.
  • Annual changes were most pronounced in 2022 — EBITDA Margin tumbled 4043 bps — and 2023, when it soared 4116 bps.
  • Tracing TEVJF's EBITDA Margin over 5 years: stood at 24.2% in 2022, then soared by 170 bps to 16.96% in 2023, then sank by 106 bps to 1.0% in 2024, then soared by 737 bps to 6.37% in 2025, then plunged by 188 bps to 5.58% in 2026.
  • The last three EBITDA Margin figures came in at 5.58% (Q2 2026), 16.37% (Q1 2026), and 6.37% (Q4 2025), per Business Quant data.

Peer Comparison

Historic Data

Download Data
DateValue
Jun 30, 2026 -5.58%
Mar 31, 2026 16.37%
Dec 31, 2025 6.37%
Sep 30, 2025 19.69%
Jun 30, 2025 10.90%
Mar 31, 2025 13.34%
Dec 31, 2024 -1.00%
Sep 30, 2024 -1.18%
Jun 30, 2024 -0.12%
Mar 31, 2024 -5.71%
Dec 31, 2023 16.96%
Sep 30, 2023 8.94%
Jun 30, 2023 -16.86%
Mar 31, 2023 -0.36%
Dec 31, 2022 -24.20%
Sep 30, 2022 11.79%
Jun 30, 2022 -25.54%
Mar 31, 2022 -19.48%
Dec 31, 2021 1.90%
Sep 30, 2021 16.03%